Leap Therapeutics, Inc.

NASDAQ:LPTX

2.81 (USD) • At close September 6, 2024
Bedrijfsnaam Leap Therapeutics, Inc.
Symbool LPTX
Munteenheid USD
Prijs 2.81
Beurswaarde 107,523,245
Dividendpercentage 0%
52-weken bereik 1.235 - 5
Industrie Biotechnology
Sector Healthcare
CEO Mr. Douglas E. Onsi J.D.
Website https://www.leaptx.com

An error occurred while fetching data.

Over Leap Therapeutics, Inc.

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap Therapeutics, Inc. has an

Vergelijkbare Aandelen

Immuneering Corporation logo

Immuneering Corporation

IMRX

1.18 USD

Champions Oncology, Inc. logo

Champions Oncology, Inc.

CSBR

4.25 USD

Candel Therapeutics, Inc. logo

Candel Therapeutics, Inc.

CADL

6.14 USD

KORU Medical Systems, Inc. logo

KORU Medical Systems, Inc.

KRMD

2.46 USD

Alaunos Therapeutics, Inc. logo

Alaunos Therapeutics, Inc.

TCRT

2.42 USD

Taysha Gene Therapies, Inc. logo

Taysha Gene Therapies, Inc.

TSHA

2.04 USD

TELA Bio, Inc. logo

TELA Bio, Inc.

TELA

2.75 USD

NextCure, Inc. logo

NextCure, Inc.

NXTC

1.42 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)